- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 183
Dyndrite finds House Fund for more capital
The House Fund has made its second investment in additive manufacturing software developer Dyndrite as part of a round that raised more than $10m.
Apr 17, 2019Boehringer Ingelheim regenerates Agomab
Boehringer Ingelheim Venture Fund has participated in a $23.8m round for the antibody developer spun out of University of Turin.
Apr 16, 2019Extend checks in $11m series A funding
City National Bank took part as Point72 and FinTech Collective co-led the round, which increased the online credit card platform's total funding to more than $14m.
Apr 15, 2019Pensees pins down series A funding
Computer vision and IoT technology developer Pensees has received $22.5m from investors including Foxconn and Qihoo 360.
Apr 15, 2019Sonde sounds out corporates to raise $16m
PureTech Health and Mitsubishi Tanabe Pharma took part in the Merck Group-led series A round, which will fund work developing Sonde's voice-based medical monitoring technology.
Apr 15, 2019Cullgen pulls in $16m
Sequoia China Capital and Highlight Capital co-led the GNI Group-backed cancer drug developer's series A round.
Apr 15, 2019Movo hails Mutua Madrileña for series A round
The electric scooter and moped rental platform collected $22.5m in a round led by Mutua Madrileña and backed by Cabify as it prepares to expand in Latin America.
Apr 15, 2019Corporate venturing deal net: 8-12 April 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Apr 12, 2019Inozyme hardens up with $67m
Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.
Apr 11, 2019Inozyme hardens up with $67m
Novo and Sanofi Ventures returned to reinvest in Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.
Apr 11, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


